Change in patient perception of pain on the VAS. Values are median (IQR) unless otherwise specified.
| Diagnosis | VAS Baseline | VAS After 6 Mos | p | No. Evaluable Patients |
|---|---|---|---|---|
| RA | 70 (57.75–80) | 27.5 (20–42) | < 0.001 | 54 |
| SpA | 65 (50–79) | 30 (20–40) | < 0.001 | 37 |
| Gout | 80 (66–82.5) | 20 (13.5–25.5) | < 0.001 | 11 |
| CTD | 47 (38.5–60.75) | 29.5 (23.5–36.25) | 0.0258 | 6 |
| PMR | 75 (68–80) | 20 (10–39.5) | < 0.001 | 19 |
| Other inflammatory | 62 (42–69) | 28 (9.5–43) | < 0.001 | 11 |
| OA | 50 (38–65) | 40 (28–52) | < 0.001 | 77 |
| FMS/CSS | 62 (40.5–76.25) | 64.5 (32–70.75) | 0.522 | 8 |
| Other noninflammatory | 60 (40–70) | 37 (10–50) | < 0.001 | 51 |
| All patients | 63 (46.25–75.75) | 30.5 (20–50) | < 0.001 | 274 |
VAS: visual analog scale; IQR: interquartile range; RA: rheumatoid arthritis; SpA: spondyloarthritis; CTD: connective tissue disease; PMR: polymyalgia rheumatica; OA: osteoarthritis; FMS: fibromyalgia syndrome; CSS: central sensitivity syndrome.